Management and Assessment of the Pharmaceutical Supply Chain

Product manufacturers require proficient oversight and development of clinical and commercial supply chain logistics to guarantee a continuous supply of products to the clinic and the market. DSI offers logistical oversight from the attainment of raw materials to start the process through to distribution of clinical materials to experimental sites for developmental programs and distributors for commercial products.

Image Credit: DS InPharmatics 

Strategy, implementation and on-going supply chain assessment assistance

DSI experts in API (Active Pharmaceutical Ingredient) and Drug Product manufacturing can give guidance to companies during all business aspects. This guidance could influence the supply chain, including the planning of production, sourcing raw materials, materials planning, choosing vendors, cost of goods, inventory planning, and supply redundancies and integrity. DSI can prepare firms for launch, helping to bring novel production facilities online and novel goods to market.


  • End-to-end supply chain assessment and optimization
  • Planning and management of technology transfer
  • Selection of vendors
  • Vendor audits and management
  • Evaluation of cost of goods
  • Strategy for inventory and contingency


  • A supply chain that is fully optimized
  • Lower costs throughout the supply chain and to final product
  • Enhanced vendor quality, reliability and integrity
  • Contingency planning and supply chain redundancy

About DS InPharmatics 

DS InPharmatics (DSI) provides regulatory, technical, and project management consulting services to healthcare product companies that manufacture and/or market pharmaceuticals, biopharmaceuticals, and cellular and gene therapy products.

Since 2007 we have provided our clients with innovative strategies and exceptional quality work products intended to enhance product development, approval, and marketing presence. Whether advocating CMC strategy, directing CMC operations or developing CMC submission content that represent the best interests of emerging biotech, we focus on the critical CMC issues and build programs that enhance development.

Sponsored Content Policy: publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Mar 14, 2024 at 10:20 AM


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    DSI, a PLG Company. (2024, March 14). Management and Assessment of the Pharmaceutical Supply Chain. News-Medical. Retrieved on April 15, 2024 from

  • MLA

    DSI, a PLG Company. "Management and Assessment of the Pharmaceutical Supply Chain". News-Medical. 15 April 2024. <>.

  • Chicago

    DSI, a PLG Company. "Management and Assessment of the Pharmaceutical Supply Chain". News-Medical. (accessed April 15, 2024).

  • Harvard

    DSI, a PLG Company. 2024. Management and Assessment of the Pharmaceutical Supply Chain. News-Medical, viewed 15 April 2024,

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.